— Know what they know.
Not Investment Advice

AURA NASDAQ

Aura Biosciences, Inc.
1W: +1.5% 1M: -18.8% 3M: -14.1% YTD: +14.9% 1Y: -1.0% 3Y: -34.0%
$6.09
+0.05 (+0.83%)
 
Weekly Expected Move ±5.5%
$5 $6 $6 $6 $7
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 30 · $629.9M mcap · 65M float · 1.07% daily turnover · Short 63% of daily vol
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$629.9M
52W Range4.73-9.54
Volume2,098,985
Avg Volume693,333
Beta0.40
Dividend—
Analyst Ratings
8 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEONatalie C. Holles
Employees113
SectorHealthcare
IndustryBiotechnology
IPO Date2021-10-29
85 Bolton Street
Boston, MA 02135
US
617 500 8864
About Aura Biosciences, Inc.

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

Recent Insider Trades

NameTypeSharesPriceDate
Kratz Erica A-Award 100,885 — 2026-09-01
Kratz Erica A-Award 199,115 $7.43 2026-09-01
Hopkins Janet Jill A-Award 58,850 — 2026-09-01
Hopkins Janet Jill A-Award 116,150 $7.43 2026-09-01
Elazzouzi Amy A-Award 23,540 — 2026-09-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms